Stock BIXT BIOXYTRAN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Bioxytran, Inc.

Equities

BIXT

US09075D1028

Market Closed - OTC Markets
Other stock markets
 20:58:48 28/06/2024 BST 		5-day change 1st Jan Change
0.0964 USD +2.55% Intraday chart for Bioxytran, Inc. +4.78% -35.73%
04-19 Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-19 Bioxytran, Inc. Announces Board Changes CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Bioxytran, Inc. Announces Board Changes
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Bioxytran, Inc. Announces Preprint of Shingles Case Study Showing Clearance Using A Topical Galectin-3 Antagonist
Bioxytran, Inc.'S Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for Covid-19
Bioxytran, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bioxytran, Inc. Receives Clearance of its Investigational New Drug Application from U.S. Food and Drug Administration to Initiate Clinical Trials of ProLectin-M
Bioxytran, Inc. Initiates A Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID 19 Patients
Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
China metals export curbs lift shares in US producer MP Materials
China rare earth curbs lift shares in U.S. producer MP Materials
Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Bioxytran, Inc. Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt
Bioxytran, Inc. Announces Positive Phase 2 Trial Results
Bioxytran, Inc. Announces Vitro Testing At Foundation for Neglected Disease Research in Bangalore India
Bioxytran, Inc. Receives Approval to Initiate Trials with Prolectin-I
Bioxytran, Inc. Announces Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
Bioxytran Establishes Indian Subsidiary Pharmalectin India Private Limited in Preparation of Commercialization
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIXT Stock
  4. News Bioxytran, Inc.
  5. Other languages